Your browser doesn't support javascript.
loading
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment.
Liu, Jiye; Hideshima, Teru; Xing, Lijie; Wang, Su; Zhou, Wenrong; Samur, Mehmet K; Sewastianik, Tomasz; Ogiya, Daisuke; An, Gang; Gao, Shaobing; Yang, Li; Ji, Tong; Bianchi, Giada; Wen, Kenneth; Tai, Yu-Tzu; Munshi, Nikhil; Richardson, Paul; Carrasco, Ruben; Cang, Yong; Anderson, Kenneth C.
Afiliação
  • Liu J; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Hideshima T; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Xing L; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Wang S; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China.
  • Zhou W; Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
  • Samur MK; Oncology and Immunology Unit, Research Service Division, WuXi AppTec (Shanghai) Co., Ltd., Shanghai 200131, China.
  • Sewastianik T; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Ogiya D; Department of Biostatistics and Computational Biology, Harvard T.H. Chan School of Public Health, Boston, 02115 MA, USA.
  • An G; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Gao S; Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw 02776, Poland.
  • Yang L; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Ji T; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300020, China.
  • Bianchi G; The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
  • Wen K; Multiple Myeloma Treatment Center and Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
  • Tai YT; Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310020, China.
  • Munshi N; Division of Hematology, Department of Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Richardson P; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Carrasco R; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Cang Y; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Anderson KC; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Sci Adv ; 7(23)2021 06.
Article em En | MEDLINE | ID: mdl-34088671
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Agentes de Imunomodulação / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Sci Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Agentes de Imunomodulação / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Sci Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos